Asset profile

Methylprednisolone

Small molecule

ApprovedGlucocorticoid receptorNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved — Asthma

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

This drug's registrational program predates the public trial registry, so its Featured trials section is empty by necessity, not by omission.

How the evidence outlook works ↗

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
August 2026 (1)
Phase 1/2Coronary Artery Disease, Systemic Inflammatory Response Syndrome, Postoperative ComplicationsNot yet recruiting
Est. primary completion 2026-08-31 · NCT07101367 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (3)
January 2027 (1)
Phase 2Plasma Cell Myeloma RefractoryRecruiting
Est. primary completion 2027-01-08 · NCT06356571 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)
Phase 1/2Crohn DiseaseRecruiting
Est. primary completion 2027-09-30 · NCT04224558 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 3Optic NeuritisRecruiting
Est. primary completion 2027-12 · NCT07623668 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (5)
March 2028 (1)
Phase 3Myocarditis AcuteRecruiting
Est. primary completion 2028-03 · NCT05150704 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)
Phase 2Lupus NephritisRecruiting
Est. primary completion 2028-06-15 · NCT05039619 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)
Phase 2AsthmaRecruiting
Est. primary completion 2028-08-14 · NCT07455396 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)
Phase 2Crohn DiseaseRecruiting
Est. primary completion 2028-10 · NCT03219359 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)
Phase 2Multiple SclerosisRecruiting
Est. primary completion 2028-12-31 · NCT02784210 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
October 2030 (1)
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2030-10-14 · NCT04270409 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
December 2031 (1)
Phase 3Lupus Nephritis, Systemic Lupus Erythematosus (SLE)Recruiting
Est. primary completion 2031-12 · NCT04702256 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.